Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myeloma

Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myelomaПодробнее

Safety and efficacy of teclistamab in patients with triple-class exposed R/R myelomaПодробнее

Approval of teclistamab in triple-class refractory multiple myelomaПодробнее

Evaluating Teclistamab in Relapsed and/or Refractory Multiple MyelomaПодробнее

Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatambПодробнее

Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myelomaПодробнее

Teclistamab for RRMM: Long term follow up data from MajesTEC-1Подробнее

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 ResultsПодробнее

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myelomaПодробнее

Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022Подробнее

Teclistamab + talquetamab targeting BCMA and GPRC5D shows promising efficacy in patients with RRMMПодробнее

Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMMПодробнее

Updated Results from MajesTEC-1 Study in Relapsed/Refractory Multiple MyelomaПодробнее

Updated data: Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibodyПодробнее

FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapiesПодробнее

Linvoseltamab versus teclistamab for TCE RRMM and the sequencing of bispecifics with CAR-TsПодробнее

Safety and efficacy of elranatamab in RRMM & prior BCMA therapies: Analysis from MagnetisMM studiesПодробнее

Real-world study determining the safety and efficacy of teclistamab in R/R multiple myelomaПодробнее

Efficacy & Safety of Approved & Emerging BCMA-directed Therapies in Multiple MyelomaПодробнее